Neurotherapeutics 20 (2), 339358
102 CovaE.BongioanniP.CeredaC.MetelliM
This helps maximize benefits while minimizing potential risks

Disclosures: Erick Cruz Grave: Nothing to Disclose, Connie Chan: Nothing to Disclose, Michael Corwin: Corcept Therapeutics: Consultant, Richard Dean: Nothing to Disclose, Sandeep Dhaliwal: Nothing to Disclose, Maryam Yazdanfar: Nothing to Disclose, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support 2344 SIGNIFICANCE OF HETEROGENEOUS BILIARY EPITHELIAL SENESCENCE AS A POSSIBLE TARGET OF NEW THERAPIES IN PRIMARY BILIARY CHOLANGITIS Motoko Sasaki 1 Yasunori Sato 1 Yasuni Nakanuma 2 , 1 Kanazawa university, 2 Fukui Saiseikai Hospital Background: New therapeutic strategies are demanded for the patients with primary biliary cholangitis (PBC) showing inadequate response for ursodeoxycholic acid (UDCA) therapy

[63] A Stanford University School of Medicine meta-analysis of clinical studies on the subject published in early 2007 showed that the application of GH on healthy elderly patients increased muscle by about 2 kg and decreased body fat by the same amount
Buy Canada drugs with confidence from the most trusted online Canadian pharmacy for over 15 years